Register to chat with like-minded investors on our interactive forums.
Period:
Draw Mode:
| Volume | 32,086 |
|
|||||
| News | - | ||||||
| Day High | 1.278 | Low High |
|||||
| Day Low | 1.23 | ||||||
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Aptose Biosciences Inc | APTO | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded
|
|
|---|---|---|---|---|
| 0.03 | 2.44% | 1.26 | 10:34:51 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 1.25 | 1.23 | 1.278 | 1.23 |
| Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
|---|---|---|---|---|---|
| 133 | 32,086 | $ 1.25 | $ 40,045 | - | 1.20 - 8.70 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 10:34:51 | 1,000 | $ 1.26 | USD |
Aptose Biosciences Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 502.35M | 7.54M | - | 0 | -51.21M | -6.79 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
Aptose Biosciences News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical APTO Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 1.29 | 1.34 | 1.20 | 1.26 | 32,095 | -0.03 | -2.33% |
| 1 Month | 1.54 | 1.7203 | 1.20 | 1.46 | 76,772 | -0.28 | -18.18% |
| 3 Months | 1.97 | 2.20 | 1.20 | 1.71 | 80,650 | -0.71 | -36.04% |
| 6 Months | 2.29 | 3.32 | 1.20 | 2.03 | 75,561 | -1.03 | -44.98% |
| 1 Year | 7.125 | 8.70 | 1.20 | 4.40 | 91,170 | -5.87 | -82.32% |
| 3 Years | 75.00 | 87.60 | 1.20 | 30.70 | 438,877 | -73.74 | -98.32% |
| 5 Years | 28.95 | 138.7875 | 1.20 | 64.39 | 778,566 | -27.69 | -95.65% |
Aptose Biosciences Description
| Aptose Biosciences Inc is a clinical-stage biotechnology company committed to discovering and developing personalized therapies addressing unmet medical needs in oncology. The company has two clinical-stage programs and a second program that is discovery-stage and partnered with another company. Luxeptinib, its panFMS-like tyrosine kinase 3 / pan-Bruton's tyrosine kinase inhibitor, is enrolling patients in a Phase 1, multicenter, open label, dose-escalation study with expansions to assess the safety, tolerability, PK, and preliminary efficacy of CG-806 in patients with chronic lymphocytic leukemia (CLL/SLL) or non-Hodgkin lymphomas (NHL). HM43239 is an oral potent myeloid kinome inhibitor, targeting a constellation of kinases operative in myeloid malignancies. |
